Pharmaceutical major Glenmark Pharmaceuticals’ subsidiary Glenmark Generics (GGL) has received ANDA approval from United States Food and Drug Administration (USFDA) for Alclometasone Dipropionate Cream, 0.05% and will start marketing and distribution of same in US market very soon.
Alclometasone Dipropionate is a low to medium potency corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. The product is targeted for niche category in dermatology segment, which has limited competition.
Presently GGL is authorized to market 11 topical semi-solids in United States. It continues to explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.